WO2012016314A9 - Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain - Google Patents

Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain Download PDF

Info

Publication number
WO2012016314A9
WO2012016314A9 PCT/BR2011/000275 BR2011000275W WO2012016314A9 WO 2012016314 A9 WO2012016314 A9 WO 2012016314A9 BR 2011000275 W BR2011000275 W BR 2011000275W WO 2012016314 A9 WO2012016314 A9 WO 2012016314A9
Authority
WO
WIPO (PCT)
Prior art keywords
derived
arachidonic acid
substituted compounds
treating pain
coxib
Prior art date
Application number
PCT/BR2011/000275
Other languages
French (fr)
Portuguese (pt)
Other versions
WO2012016314A1 (en
Inventor
André AUGUSTO GOMES FARACO
Janetti Nogueira De Francischi
Rafael Machado Rezende
Patrícia PAIVA LIMA
Webster Glayser Pimenta Dos Reis
Original Assignee
Universidade Federal De Minas Gerais - Ufmg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De Minas Gerais - Ufmg filed Critical Universidade Federal De Minas Gerais - Ufmg
Publication of WO2012016314A1 publication Critical patent/WO2012016314A1/en
Publication of WO2012016314A9 publication Critical patent/WO2012016314A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The present invention describes the production of arachidonic acid-derived coxib analogue-substituted compounds and salts thereof for use in treating pain. Furthermore, the invention relates to pharmaceutical compositions containing arachidonic acid-derived coxib analogue-substituted compounds, salts thereof and pharmaceutically acceptable excipients for use in treating pain. The painkillers comprised by the invention can be used alone or in combination with other painkillers, for relieving slight, moderate or severe pain.
PCT/BR2011/000275 2010-08-04 2011-08-04 Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain WO2012016314A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI1003050-6A BRPI1003050B1 (en) 2010-08-04 2010-08-04 ARACHIDONIC ACID DERIVED COMPOUNDS REPLACED WITH COXIBES ANALOGUES FOR PAIN TREATMENT
BRPI1003050-6 2010-08-04

Publications (2)

Publication Number Publication Date
WO2012016314A1 WO2012016314A1 (en) 2012-02-09
WO2012016314A9 true WO2012016314A9 (en) 2012-03-22

Family

ID=45558870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000275 WO2012016314A1 (en) 2010-08-04 2011-08-04 Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain

Country Status (2)

Country Link
BR (1) BRPI1003050B1 (en)
WO (1) WO2012016314A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7161016B1 (en) * 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US20040122089A1 (en) * 2001-06-20 2004-06-24 Martin Billy R. Novel eicosanoid analgesics
US20040092566A1 (en) * 2002-11-12 2004-05-13 Graneto Matthew J. Celecoxib prodrug
US20070105940A1 (en) * 2005-10-19 2007-05-10 Allergan, Inc. Method for treating pain

Also Published As

Publication number Publication date
BRPI1003050B1 (en) 2021-05-25
WO2012016314A1 (en) 2012-02-09
BRPI1003050A2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2012075362A3 (en) Chemokine cxcr4 receptor modulators and used related thereto
WO2011085162A3 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2014011750A8 (en) Laquinimod formulations without alkalizing agent
SG10201501579WA (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
MX363389B (en) Pharmaceutical composition comprising amorphous ivabradine.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
MX2015008171A (en) Formulation comprising amorphous agomelatine.
MX363558B (en) Pharmaceutical compositions comprising flurbiprofen.
WO2012016314A9 (en) Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain
WO2013038200A3 (en) Neurodevelopmental disorders
WO2011107921A3 (en) Modified release composition of milnacipran
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813972

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813972

Country of ref document: EP

Kind code of ref document: A1